Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prognostic Values of Chest/Abdominal Wall Varices and Spider Nevi in Patients With Liver Cirrhosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02468479
Recruitment Status : Completed
First Posted : June 10, 2015
Last Update Posted : April 19, 2017
Sponsor:
Information provided by (Responsible Party):
Xingshun Qi, General Hospital of Shenyang Military Region

Tracking Information
First Submitted Date June 4, 2015
First Posted Date June 10, 2015
Last Update Posted Date April 19, 2017
Study Start Date June 2015
Actual Primary Completion Date December 2016   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: June 6, 2015)
  • Prevalence and type of chest/abdominal wall varices and spider nevi [ Time Frame: 1.5 years ]
    Baseline data
  • Association between etiology of liver cirrhosis and type of chest/abdominal wall varices and spider nevi [ Time Frame: 1.5 years ]
    Baseline data
  • Association between degree of liver function and type of chest/abdominal wall varices and spider nevi [ Time Frame: 1.5 years ]
    Baseline data
  • Effect of chest/abdominal wall varices and spider nevi on survival [ Time Frame: 2.5 years or more ]
    Follow-up data
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Prognostic Values of Chest/Abdominal Wall Varices and Spider Nevi in Patients With Liver Cirrhosis
Official Title Prognostic Values of Chest/Abdominal Wall Varices and Spider Nevi in Patients
Brief Summary Chest/abdominal wall varices and spider nevi are two common presenting signs of liver cirrhosis. Their prognostic values remain unclear.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population Patients with a diagnosis of liver cirrhosis who are consecutively admitted to our department.
Condition Liver Cirrhosis
Intervention Other: No relevant intervention.
No relevant intervention.
Study Groups/Cohorts Not Provided
Publications * Li H, Wang R, Méndez-Sánchez N, Peng Y, Guo X, Qi X. Impact of spider nevus and subcutaneous collateral vessel of chest/abdominal wall on outcomes of liver cirrhosis. Arch Med Sci. 2019 Mar;15(2):434-448. doi: 10.5114/aoms.2018.74788. Epub 2018 Mar 28.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: June 6, 2015)
200
Original Estimated Enrollment Same as current
Actual Study Completion Date December 2016
Actual Primary Completion Date December 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  1. Liver cirrhosis.
  2. Consecutive admission.
  3. Permitted to physical examinations.
  4. Informed consents.

Exclusion Criteria:

  1. Non-cirrhotic portal hypertension.
  2. Malignancy.
  3. Uncontrolled infection.
  4. Severe chronic diseases.
  5. Poor patient compliance.
Sex/Gender
Sexes Eligible for Study: All
Ages Child, Adult, Older Adult
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries China
Removed Location Countries  
 
Administrative Information
NCT Number NCT02468479
Other Study ID Numbers CAWV-LC
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Xingshun Qi, General Hospital of Shenyang Military Region
Study Sponsor General Hospital of Shenyang Military Region
Collaborators Not Provided
Investigators
Principal Investigator: Xiaozhong Guo, MD, PhD Department of Gastroenterology, General Hospital of Shenyang Military Area
PRS Account General Hospital of Shenyang Military Region
Verification Date April 2017